Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA

1,125 patients combined in both studies Efficacy data available after the 6-month dosing NEW YORK, Oct. 16, 2020 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following Shareholder Update from Chief Executive Officer Nadav Kidron. Dear […]

Join our mailing list

Skip to content